Upsher-Smith announces exclusive agreement with emerging pharmaceutical company

Upsher-Smith Laboratories Inc. recently announced it has entered into an exclusive agreement with an emerging pharmaceutical company for the marketing and distribution of a generic central nervous system (CNS) product.

IMS Health reported that recent sales in the United States of the product totaled more than $200 million for a 12-month period ending in June of this year. The new partnership is part of Upsher-Smith’s effort to increase its generic portfolio and its expansion into strategic partnerships in the pharmaceutical industry.

"Upsher-Smith has long been recognized within the pharmaceutical industry as a trusted name in the generics marketplace," Upsher-Smith President Rusty Field said. "This new agreement demonstrates the company's commitment to expanding its portfolio of high-quality, high-value generic products for patients."

Under the terms of the agreement, Upsher-Smith’s partner will have exclusivity to the development, manufacturing and supplying of the product while Upsher-Smith markets and distributes it in the U.S. under its own label. The financial terms of the deal have not yet been released.